AAP
FULC icon

Arax Advisory Partners’s Fulcrum Therapeutics FULC Stock Holding History

Arax Advisory Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.76K Buy
1,848
+1,737
+1,565% +$10.6K ﹤0.01% 4505
2026
Q1 		$852 Sell
111
-70
-39% -$649 ﹤0.01% 3329
2025
Q4 		$2.05K Buy
+181
New +$1.84K ﹤0.01% 3249

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's FULC Position: Q2 2026 in Review

Arax Advisory Partners increased its Fulcrum Therapeutics (FULC) stake by 1,565% in Q2 2026, buying an estimated $10.6K and bringing the position to 1,848 shares worth $6.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4505.

Arax Advisory Partners first reported a position in FULC in Q4 2025 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Arax Advisory Partners held 1,848 shares of Fulcrum Therapeutics worth $6.76K as of Q2 2026.
  • Arax Advisory Partners bought 1,737 Fulcrum Therapeutics shares in Q2 2026, an estimated $10.6K.
  • Fulcrum Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4505 holding.
  • Arax Advisory Partners first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.